Table 3.

Health outcome and direct medical costs for 3 vaccination scenarios in year 1^A.

	Varicella outcomes and costs				Budget impact
	No vaccination	Highly effective	Moderately effective	Weakly effective	Highly effective	Moderately effective	Weakly effective
Varicella cases	2,010,002	1,592,234	1,627,378	1,677,143	−417,768	−382,624	−332,859
Varicella deaths	283	227	230	235	−56	−53	−48
Total annual costs B	4,977,538,459	4,416,333,877	4,461,552,395	4,550,194,779	−561,204,582	−515,986,064	−427,343,680
Vaccine acquisition	0	471,721,386	424,450,951	381,553,255	471,721,386	424,450,951	381,553,255
Vaccine administration	0	27,582,782	27,566,853	27,544,782	27,582,782	27,566,853	27,544,782
Varicella treatment	4,977,538,459	3,917,029,709	4,009,534,591	4,141,096,742	−1,060,508,749	−968,003,868	−836,441,717
Varicella treatment costs, by visit type B
Inpatient costs	4,239,721,087	3,332,168,753	3,411,993,657	3,525,544,845	−907,552,334	−827,727,431	−714,176,243
Outpatient costs	737,817,372	584,860,956	597,540,934	615,551,897	−152,956,416	−140,276,437	−122,265,474

^A For 3 vaccine types (highly, moderately, and weakly effective) at 95% coverage.

^B All costs are presented in undiscounted 2015 MXN.